Flamel Technologies Report issue

For profit Phase 2 Phase 3
Founded: Vennisieux France (1990)
Status: Acquired by Avadel Pharmaceuticals (2017)

Organization Overview

First Clinical Trial
2010
NCT01010646
First Marketed Drug
2016
ephedrine
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Flame Biosciences | Flamel Ireland Limited | FLAMEL IRELAND LTD

Active Ingredients

Marketed Drugs (2)

ephedrine (2016)

methylene blue (proveblue) (2016)

Drugs in Phase 3 Trials (1)

sodium oxybate (xyrem) (1 trial)

Drugs in Phase 2 Trials (5)

fl-101 (3 trials)

fl-301 (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

nivolumab (opdivo) (1 trial)

ribavirin (virazole) (1 trial)

Indications

Approved Indications


 

Brain Diseases

Methemoglobinemia

Neoplasms

Skin Diseases, Infectious

Urinary Tract Infections

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cataplexy (Phase 3)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis C (Phase 2)

Hepatitis C, Chronic (Phase 2)

Hepatitis, Chronic (Phase 2)

Narcolepsy (Phase 3)

Sleepiness (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 6